Strides Pharma Science (STAR) Fundamentals 2026 — P/E 17.2x, Revenue Analysis | SniperIQ
Strides Pharma Science (STAR) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹9,574 Crore, trading at ₹1040.50 on the BSE. This SniperIQ fundamentals page covers Strides Pharma Science's valuation (P/E 17.2x, P/B 3.1x), profitability (net margin 11.4%), revenue (₹4,859 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Strides Pharma Science's market cap?
Strides Pharma Science (STAR) has a market capitalization of approximately ₹9,574 Crore, trading at ₹1040.50 on the BSE. Market cap moves with the live share price.
What is Strides Pharma Science's P/E ratio?
Strides Pharma Science's trailing twelve-month P/E ratio is 17.2x, with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Strides Pharma Science?
Strides Pharma Science runs a net profit margin of 11.4%, a gross margin of 36.4%, and an operating margin of 14.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Strides Pharma Science generate?
Strides Pharma Science reported revenue of ₹4,859 Crore for fiscal year 2026, with net income of ₹556 Crore and earnings per share (EPS) of 60.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Strides Pharma Science pay a dividend?
Strides Pharma Science offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Strides Pharma Science financially healthy?
Strides Pharma Science carries a debt-to-equity ratio of 0.57x and a current ratio of 1.25x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Strides Pharma Science a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Strides Pharma Science (STAR) the key facts are: market cap ₹9,574 Crore, P/E 17.2x, revenue ₹4,859 Crore, 52-week range 769.6-1231.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Strides Pharma Science's full fundamentals live
Get Strides Pharma Science's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.